Astralis Ltd Reports First Half 2003 Results.Business Editors/Health/Medical Writers FAIRFIELD, N.J.--(BUSINESS WIRE)--Aug. 12, 2003 Astralis Ltd (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : ASTR ASTR American Society for Theatre Research (established in 1956) ASTR Aerospace Systems Test Reactor ASTR Aircraft Shield Test Reactor ASTR Automatic Spectral Target Recognition ASTR Army Specialized Training Reserve ) announced today its results for the period ending June 30, 2003. For the period from January 1, 2003 through June 30, 2003, the Company recorded a net loss of $2.8 million, or $0.07 per share. The Company, which is in the development stage, had no revenue during this period. Total stockholders' equity Stockholders' Equity The portion of the balance sheet that includes capital received from investors in exchange for stock (paid-in capital), donated capital, and retained earnings. This is equal to total assets minus liabilities, preferred stock and intangible assets. was $ 8.3 million as of June 30, 2003 and the Company had cash and marketable security marketable security A security that may be resold by one investor to another. Most securities are marketable; they develop secondary markets for trading. Also called negotiable security. balances totalling $ 2.5 million as of June 30, 2003. Research and development expenses amounted to $2.1 million for the period ending June 30, 2003. This includes spending on preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. for PsoraxineTM, the Company's first drug candidate for the treatment of Psoriasis.
Astralis Ltd.
(A Development Stage Entity)
Selected Statement of Operation Information (Unaudited)
January 1, 2003 to June 31 2003
Revenues $--
Total Operating Expenses 2,851,687
Loss from Operations ($ 2,851,687)
Other Income
Investment Income $85,027
Net Loss to Common Stockholder $(2,766,660)
Basic and diluted loss per common share $(0.07)
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion